Roche agrees to buy a developer of a drug for people suffering from inflammatory bowel disease from Roivant Sciences and Pfizer in a deal worth up to $7.25 billion, Textainer is being acquired for about $2.1 billion, and Microsoft and Alphabet lead a busy earnings week.
These Stocks Are Moving the Most Today: Roivant Sciences, Textainer, Okta, Microsoft, Alphabet
2023-10-23 16:50
Roche agrees to buy a developer of a drug for people suffering from inflammatory bowel disease from Roivant Sciences and Pfizer in a deal worth up to $7.25 billion, Textainer is being acquired for about $2.1 billion, and Microsoft and Alphabet lead a busy earnings week.
You Might Like...
FIFA 23 FUTTIES Week 1 Objectives: How to Complete
Is Adin Ross homophobic? Kick streamer dubs Nickmercs 'great American' amid Pride Month controversy: 'You stand up for what's right'
Iron Man game to be made with regular feedback from Marvel fans
Who stars in 'Hack My Home' Season 1? Netflix's Dream Team ready to make family house renovation a success
Horizon Forbidden West shifts 8.4 million units
The Texas Chain Saw Massacre teams wants you to play other villains, not just Leatherface
Twitter is producing errors. What we know.
Two new characters join Tekken 8